25 Million Americans on GLP-1s Is Not a Projection. It’s a Trajectory
GLP-1 adoption is scaling at a pace few healthcare categories have seen before.
Estimates suggest usage could reach 25 million Americans by 2030, up from approximately 5 million users in 2023 and 10 million by 2025, according to data from JPMorgan.
That kind of growth doesn’t happen in stable markets.
It happens when multiple forces align at the same time.
The global market is projected to approach $200 billion, driven by demand for weight loss, metabolic health, and long-term treatment. At the same time, new delivery formats, including oral GLP-1s, are reducing friction and making adoption easier for a broader population.
This is no longer early adoption.
It’s rapid scale.
Why GLP-1 Adoption Is Accelerating So Quickly
The growth isn’t random. It’s structural.
Several key shifts are removing barriers that previously limited adoption:
Oral GLP-1 medications are one of the most important developments.
By removing the need for injections, they reduce psychological and logistical friction for many consumers. That alone expands the addressable market significantly.
Access is also improving.
Coverage discussions across Medicare and Medicaid are opening the door for broader reimbursement. At the same time, pricing pressure is increasing as competition grows, with some projections pointing toward significantly lower monthly costs over time.
Global expansion and the introduction of generics will push adoption even further.
When access increases, usage follows. And when usage scales, competition increases with it.
More Access Means More Competition
This is where many brands misread the opportunity.
Rising demand creates visibility, but it also attracts more participants.
As GLP-1 adoption increases, more telehealth providers, clinics, pharmacies, and consumer health brands enter the market.
That creates pressure across multiple dimensions.
Customer acquisition costs increase as more advertisers compete for the same audiences. Messaging becomes more constrained as compliance requirements tighten. Consumers become more selective as they evaluate more options.
The result is a market that grows rapidly while becoming harder to win in.
Growth does not remove competition - it amplifies it.
GLP-1s Are Reshaping Entire Industries
The impact of GLP-1 adoption extends far beyond healthcare.
As usage increases, downstream effects are already being observed across multiple sectors.
Food and beverage companies are seeing changes in consumer behavior, including reduced calorie intake and shifts in purchasing patterns. Some estimates suggest potential revenue impacts in the tens of billions as consumption patterns adjust.
Healthcare systems are also affected.
GLP-1s are not just short-term treatments. They influence long-term chronic care, metabolic health, and preventative outcomes. That changes how patients interact with the system over time.
Consumer behavior itself is shifting.
People on GLP-1s often change how they eat, how frequently they consume food, and how they think about health more broadly. These changes extend into lifestyle, purchasing habits, and long-term decision-making.
This is not just a pharmaceutical trend - it is a behavioral shift.
What Winning Brands Are Building Now
As the market evolves, the brands that perform well are not relying on demand alone.
They are building systems that allow them to operate effectively in a more complex environment.
Step 1: Build Compliance-First Infrastructure
Regulatory scrutiny is increasing as the category grows.
Brands that integrate compliance into their messaging, funnels, and operations from the beginning are able to scale more consistently. Those that treat it as an afterthought often face restrictions that limit growth.
Step 2: Expand Beyond Single-Channel Acquisition
Relying on a single platform is becoming riskier.
High-performing brands are combining multiple acquisition channels, including Meta, Google, and owned media, to diversify traffic sources and maintain stability as costs fluctuate.
Step 3: Strengthen Onboarding and Retention
GLP-1 is inherently recurring.
Patients remain on treatment for extended periods, which creates a strong opportunity to increase lifetime value. Brands that invest in onboarding, education, and ongoing engagement are able to retain more users and reduce reliance on constant acquisition.
Step 4: Build Fast Testing Systems
Creative performance continues to drive acquisition.
Brands that test quickly, iterate consistently, and scale winning variations are able to maintain performance even as competition increases. Speed becomes a key advantage.
Step 5: Optimize the Full Funnel
As costs rise, conversion matters more.
From first click to onboarding, every step in the funnel needs to be clear, simple, and efficient. Brands that improve conversion rates are able to scale more effectively with the same level of traffic.
This Is No Longer a Launch Market
Many brands are still approaching GLP-1 as if they are early - they focus on launching offers, testing basic acquisition, and validating demand.
That phase has already passed.
The market is entering a stage where execution determines outcomes.
Success depends on how well a brand can manage acquisition costs, maintain compliance, retain customers, and optimize performance across the entire system.
This is no longer about entering the market, it's about operating within it.
